Pharmaceutical News

RSS

Can-Fite reports further progress in continuing preclinical program of CF602 sexual dysfunction drug

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported further progress in its continuing preclinical program of its CF602 drug candidate as the Company prepares to file an investigational new drug (IND) application with the U.S. Food and Drug Administration to allow the initiation of a Phase I clinical study.

29 Jun 2015

Egalet reports positive results from Category 3 abuse-deterrent intranasal HAL study

Egalet Corporation today announced positive results from a Category 3 intranasal human abuse liability (HAL) study of Egalet-001, an abuse-deterrent, extended-release, oral morphine formulation in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.

29 Jun 2015

Cosmederm Bioscience expands TriCalm's line of anti-itch products to further benefit sufferers of itch

Cosmederm Bioscience, Inc. today announced the expansion of its itch-relief product line, TriCalm, with the new TriCalm Clinical Repair Cream and TriCalm Extra Strength Spray. Following the success of the company's initial product, TriCalm Hydrogel, these two new offerings strategically expand the brand's line of steroid-free, anti-itch products to further benefit sufferers of itch.

29 Jun 2015

Spinifex Pharmaceuticals enters into agreement to be acquired by Novartis

Spinifex Pharmaceuticals, Inc., a company focused on the development of new drugs for the treatment of chronic pain, today announces that it has agreed to the sale of Spinifex to Novartis International AG, for an upfront cash consideration of US$200 million plus undisclosed clinical development and regulatory milestone payments.

29 Jun 2015

Artemisinin and the fight against malaria: an interview with Dr. Robert Sebbag, Sanofi

Since 2014, more than 16 million anti-malarial treatments derived from the Sanofi patented process for semi-synthetic artemisinin have been supplied to endemic countries in Africa.

From Sanofi 28 Jun 2015

Adding tamper resistant properties to medications can help curb prescription drug abuse

Health Canada today published a Notice of Pre-Consultation in Canada Gazette, Part I, seeking stakeholder feedback on draft Tamper-Resistant Properties of Drugs Regulations.

27 Jun 2015

Study identifies effective market research approaches for understanding payer decision-making

The U.S. Supreme Court's ruling this week in support of the Affordable Care Act was good news for the health insurance industry. If the court had ruled against the government, insurers were at risk of losing millions of customers.

27 Jun 2015

Study suggests link between fatalistic beliefs and completion of HPV vaccine series among Appalachian women

Could a fatalistic attitude toward cervical cancer serve as a barrier to prevention of the disease? A recent study conducted by University of Kentucky researchers in the Rural Cancer Prevention Center suggests a link between fatalistic beliefs and completion of the human papillomavirus (HPV) vaccine series among a sample of young Appalachian Kentucky women.

27 Jun 2015

Study shows wide geographic variation in use of 'clotbuster' for stroke treatment

It looks like a crazy quilt spread over the continent. But a new map of emergency stroke care in America shows just how much of a patchwork system we still have for delivering the most effective stroke treatment.

27 Jun 2015

SLU researchers find way to stop growth of cancer cells by targeting the Warburg Effect

In research published in Cancer Cell, Thomas Burris, Ph.D., chair of pharmacology and physiology at Saint Louis University, has, for the first time, found a way to stop cancer cell growth by targeting the Warburg Effect, a trait of cancer cell metabolism that scientists have been eager to exploit.

26 Jun 2015

Cannabis and Cannabinoid Research journal supports President Obama's statement on medical use of marijuana

Mary Ann Liebert, publisher of the newly launched peer-reviewed open access journal Cannabis and Cannabinoid Research, strongly supports President Obama's statement that "...carefully prescribed medical use of marijuana may in fact be appropriate and we should follow the science as opposed to ideology on this issue," when asked about a pending Senate bill seeking to change federal law regarding state-legalized medical marijuana programs.

26 Jun 2015

Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced updates on its lead product candidates, XmAb®5871 and XmAb®7195, and on its XmAb® bispecific oncology pipeline.

26 Jun 2015

Wistar Institute researchers identify specific mutations responsible for ineffectiveness of flu vaccines

Viruses like influenza have the ability to mutate over time, and given that the flu vaccines administered during the 2014-2015 season were largely ineffective at preventing the spread of the flu, it appears the virus that recently circulated had taken on mutations not accounted for when last year's vaccine was developed.

26 Jun 2015

Potential new class of drugs lessen neurodegeneration in rat model of Parkinson's disease

The first test in a mammalian model of a potential new class of drugs to treat Parkinson's disease shows abatement of neurodegeneration in the brains of test rats and no significant toxicities, University of Alabama at Birmingham and Pfizer Inc. researchers report online in The Journal of Biological Chemistry.

26 Jun 2015

Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., received approval for EYLEA (aflibercept) Injection by the Ministry of Health, Labour and Welfare (MHLW) in Japan for the treatment of patients with macular edema secondary to retinal vein occlusion (RVO).

26 Jun 2015

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD (Merck & Co., Inc., Kenilworth, New Jersey, USA) today announced that on 22 June the European Commission approved SIMPONI (golimumab) for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA).

26 Jun 2015

Scientists develop small molecule drug that prevents autophagy from starting in cancer cells

As a tumor grows, its cancerous cells ramp up an energy-harvesting process to support its hasty development. This process, called autophagy, is normally used by a cell to recycle damaged organelles and proteins, but is also co-opted by cancer cells to meet their increased energy and metabolic demands.

26 Jun 2015

Pilot antibiotic program at pediatric long-term care facility decreases use of topical antibiotic

A pilot antibiotic stewardship program at a pediatric long-term care facility brought about a 59 percent decrease in use of a topical antibiotic and an 83 percent decrease in orders for antibiotics without proper documentation during a six-month period, according to a new study.

26 Jun 2015

Long-acting injectable antipsychotic medication benefits people with schizophrenia

Schizophrenia, which affects 2 million to 3 million people in the U.S., causes hallucinations, delusions and disorganization. Left untreated, the disease can cause a significant loss in quality of life, including unemployment and estrangement from loved ones. But many people with schizophrenia can control the disorder and live without symptoms for several years if they consistently take prescribed antipsychotic medication, typically a daily pill.

25 Jun 2015

Basilea announces UK launch of broad-spectrum Cephalosporin Zevtera for first-line treatment of pneumonia

Basilea Pharmaceutica AG today announces the UK launch of its broad-spectrum Cephalosporin Zevtera (Ceftobiprole medocaril) for the first-line treatment of serious bacterial pneumonia.

25 Jun 2015

Pharmaceutical News

Can-Fite reports further progress in continuing preclinical program of CF602 sexual dysfunction drug

Egalet reports positive results from Category 3 abuse-deterrent intranasal HAL study

Cosmederm Bioscience expands TriCalm's line of anti-itch products to further benefit sufferers of itch

Spinifex Pharmaceuticals enters into agreement to be acquired by Novartis

Artemisinin and the fight against malaria: an interview with Dr. Robert Sebbag, Sanofi

Adding tamper resistant properties to medications can help curb prescription drug abuse

Study identifies effective market research approaches for understanding payer decision-making

Study suggests link between fatalistic beliefs and completion of HPV vaccine series among Appalachian women

Study shows wide geographic variation in use of 'clotbuster' for stroke treatment

SLU researchers find way to stop growth of cancer cells by targeting the Warburg Effect

Cannabis and Cannabinoid Research journal supports President Obama's statement on medical use of marijuana

Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

Wistar Institute researchers identify specific mutations responsible for ineffectiveness of flu vaccines

Potential new class of drugs lessen neurodegeneration in rat model of Parkinson's disease

Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

Scientists develop small molecule drug that prevents autophagy from starting in cancer cells

Pilot antibiotic program at pediatric long-term care facility decreases use of topical antibiotic

Long-acting injectable antipsychotic medication benefits people with schizophrenia

Basilea announces UK launch of broad-spectrum Cephalosporin Zevtera for first-line treatment of pneumonia

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News